Published in: Genetic Engineering News
On: September 15, 1993
“Medical therapeutic miracles remain the primary promise of the Human Genome Project (HGP). But pharmaceutical R&D does not occur in a vacuum. Several new technologies, including novel development in DNA sequencing and mapping methods and the optimization of instrumentation, are rapidly spinning off genome scientists are now involved in taking a new discovery and turning it into a financial venture. The new technology firms cover a wide “product” area with each company attempting to find its marketing niche in a rapidly evolving industry.”
